ERBB2 and breast carcinoma: In this study, we used whole-genome methylation sequencing to characterize the methylation patterns of 28 HER2-positive breast cancer tissues, including 12 samples before neoadjuvant treatment in pCR group, 8 samples before treatment and paired 8 samples after surgery in non-pCR group.